The Investor
15 Sep 2026, 15:48
Eli Lilly Highlights Strong Retatrutide Weight-Loss Data Ahead of EASD 2026
Eli Lilly (NYSE: LLY) will present new clinical data across its obesity and diabetes portfolio at the EASD 2026 meeting, with updates covering retatrutide, Foundayo, Mounjaro and the experimental eloraTZP combination.
Among the most notable results, Lilly’s Phase 3 TRIUMPH-2 trial showed that adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 pounds, or 20.8% of body weight, over 80 weeks. A1C levels declined by as much as an average of 1.6 percentage points. Retatrutide is a once-weekly drug targeting GIP, GLP-1 and glucagon receptors.
Lilly will also unveil Phase 2 results for eloraTZP, which combines eloralintide with tirzepatide. Earlier Phase 1 data showed 17% weight loss over 16 weeks with the combination, compared with 10% for tirzepatide alone. Meanwhile, Foundayo data showed potentially favorable cardiovascular signals in patients with type 2 diabetes.
The results highlight Lilly’s strategy to build a broader next-generation obesity franchise beyond Zepbound and Mounjaro, with oral, triple-agonist and combination therapies targeting different segments of the rapidly expanding cardiometabolic market.
Eli Lilly (NYSE: LLY) will present new clinical data across its obesity and diabetes portfolio at the EASD 2026 meeting, with updates covering retatrutide, Foundayo, Mounjaro and the experimental eloraTZP combination.
Among the most notable results, Lilly’s Phase 3 TRIUMPH-2 trial showed that adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 pounds, or 20.8% of body weight, over 80 weeks. A1C levels declined by as much as an average of 1.6 percentage points. Retatrutide is a once-weekly drug targeting GIP, GLP-1 and glucagon receptors.
Lilly will also unveil Phase 2 results for eloraTZP, which combines eloralintide with tirzepatide. Earlier Phase 1 data showed 17% weight loss over 16 weeks with the combination, compared with 10% for tirzepatide alone. Meanwhile, Foundayo data showed potentially favorable cardiovascular signals in patients with type 2 diabetes.
The results highlight Lilly’s strategy to build a broader next-generation obesity franchise beyond Zepbound and Mounjaro, with oral, triple-agonist and combination therapies targeting different segments of the rapidly expanding cardiometabolic market.
